Related references
Note: Only part of the references are listed.Hyperglycemia inhibition of endothelial miR-140-3p mediates angiogenic dysfunction in diabetes mellitus
Dongni Wang et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2019)
FOXK2 Transcription Factor and Its Emerging Roles in Cancer
Gabriela Nestal de Moraes et al.
CANCERS (2019)
RHOG Activates RAC1 through CDC42 Leading to Tube Formation in Vascular Endothelial Cells
Oula El Atat et al.
CELLS (2019)
FOXK transcription factors: Regulation and critical role in cancer
Ying Liu et al.
CANCER LETTERS (2019)
The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo
Mingtao Liu et al.
THORACIC CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
The roles and role-players in thyroid cancer angiogenesis
Sadegh Rajabi et al.
ENDOCRINE JOURNAL (2019)
Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR
Feng Du et al.
THERANOSTICS (2019)
Consensus guidelines for the use and interpretation of angiogenesis assays
Patrycja Nowak-Sliwinska et al.
ANGIOGENESIS (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling
Zejun Fang et al.
CANCER LETTERS (2018)
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Lesley J. Scott
DRUGS (2018)
FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma
Fan Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Pilot Dose Comparison of Apatinib in Chinese Patients With Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
Xin Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells
Gabriela Nesta de Moraes et al.
ONCOGENESIS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA
Shuyang Wang et al.
CANCER LETTERS (2018)
Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis
Jin-min Xue et al.
ONCOTARGETS AND THERAPY (2018)
CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1 alpha/VEGF-A pathway in colorectal cancer
Zhuoqing Xu et al.
CELL DEATH & DISEASE (2018)
Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer
Haoran Feng et al.
CELL DEATH & DISEASE (2018)
FOXK2, regulted by miR-1271-5p, promotes cell growth and indicates unfavorable prognosis in hepatocellular carcinoma
Mei-Fang Lin et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2017)
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Eleonora Molinaro et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK313/ANG Signaling Pathway in nap Nastc Thyroid Cancer
Zhijian Jin et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Sox9 mediated transcriptional activation of FOXK2 is critical for colorectal cancer cells proliferation
Yu Qian et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients
Zhiyong Shi et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Lentivirus-mediated transfection of chondroitinase ABC gene without the bacterial leader sequence enables long-term secretion of functional chondroitinase ABC in human bone marrow stromal cells
Yang Guo et al.
BIOTECHNOLOGY LETTERS (2016)
FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis
Lin Shan et al.
CANCER CELL (2016)
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
Giandomenico Roviello et al.
CANCER LETTERS (2016)
Forkhead box protein k1 recruits TET1 to act as a tumor suppressor and is associated with MRI detection
Taotao Sun et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer
G. Nestal de Moraes et al.
ONCOGENESIS (2015)
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance
Maryarn A. Hamdollah Zadeh et al.
MOLECULAR ONCOLOGY (2015)
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
Xichun Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Matrix density alters zyxin phosphorylation, which limits peripheral process formation and extension in endothelial cells invading 3D collagen matrices
Colette A. Abbey et al.
MATRIX BIOLOGY (2014)
Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
Paul Mesange et al.
ONCOTARGET (2014)
The Design of a Quantitative Western Blot Experiment
Sean C. Taylor et al.
BIOMED RESEARCH INTERNATIONAL (2014)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
R. C. Smallridge et al.
CLINICAL ONCOLOGY (2010)
Investigating endothelial invasion and sprouting behavior in three-dimensional collagen matrices
Kayla J. Bayless et al.
NATURE PROTOCOLS (2009)
Technical aspects of immunohistochemistry
JA Ramos-Vara
VETERINARY PATHOLOGY (2005)
Anaplastic thyroid carcinoma - Treatment outcome and prognostic factors
E Kebebew et al.
CANCER (2005)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Share Paper
